Recent Progress of Sodium-Glucose Transporter 2 Inhibitors as Potential Antidiabetic Agents

Ban, Huazhuo; Yu, Ru-Nan; Wang, Zhijian; Zhang, Dayong

doi:10.4155/fmc-2017-0241

Cited by 8 publications

(3 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Humans with a SGLT1-inactivating mutation experience glucose malabsorption with diarrhea, dehydration, and minimal glucosuria. In contrast, individuals with a SLGT2-inactivating mutation have pronounced renal glucosuria but are otherwise healthy. − SGLT inhibitors have had significant impact for the treatment diabetes. − SGLT2-selective inhibitors are preferred due to their ability to lower blood sugar with selectivity for kidney reabsorption. Currently, there are several SGLT2 inhibitors on the market that include 61 (dapagliflozin), 63 (canagliflozin), 64 (ipragliflozin), 65 (empagliflozin), and 67 (luseogliflozin) for T2DM (Figure ).…”

Section: Metabolism Targetsmentioning

confidence: 99%

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease

Romero¹,

Jones²,

Xu³

et al. 2020

J. Med. Chem.

View full text Add to dashboard Cite

Nonalcoholic steatohepatitis (NASH) is a severe form of nonalcoholic fatty liver disease (NAFLD) characterized by liver steatosis, inflammation, and hepatocellular damage. NASH is a serious condition that can progress to cirrhosis, liver failure, and hepatocellular carcinoma. The association of NASH with obesity, type 2 diabetes mellitus, and dyslipidemia has led to an emerging picture of NASH as the liver manifestation of metabolic syndrome. Although diet and exercise can dramatically improve NASH outcomes, significant lifestyle changes can be challenging to sustain. Pharmaceutical therapies could be an important addition to care, but currently none are approved for NASH. Here, we review the most promising targets for NASH treatment, along with the most advanced therapeutics in development. These include targets involved in metabolism (e.g., sugar, lipid, and cholesterol metabolism), inflammation, and fibrosis. Ultimately, combination therapies addressing multiple aspects of NASH pathogenesis are expected to provide benefit for patients.

show abstract

Section: Metabolism Targetsmentioning

confidence: 99%

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease

Romero¹,

Jones²,

Xu³

et al. 2020

J. Med. Chem.

View full text Add to dashboard Cite

show abstract

“…Extending our earlier efforts in the area of nanocatalysis [ 5 , 6 , 7 ], in this article La 2 O 3 nanoparticles immobilized onto the chitosan matrix were prepared ( Figure 1 ) and then employed as a promising heterogeneous basic catalyst to synthesis pyridines and pyrazoles. These azines and azoles have privileged antitumor [ 12 , 13 , 14 , 15 ], antidiabetes [ 16 ], antimicrobial [ 17 , 18 ], anti-HCV [ 14 , 19 , 20 ], and antidepressant [ 21 , 22 ] activities.…”

Section: Introductionmentioning

confidence: 99%

Synthesis of Chitosan-La2O3 Nanocomposite and Its Utility as a Powerful Catalyst in the Synthesis of Pyridines and Pyrazoles

et al. 2021

View full text Add to dashboard Cite

Recently, the development of nanocatalysts based on naturally occurring polysaccharides has received a lot of attention. Chitosan (CS), as a biodegradable and biocompatible polysaccharide, is considered to be an excellent template for the design of a hybrid biopolymer-based metal oxide nanocomposite. In this case, lanthanum oxide nanoparticles doped with chitosan at different weight percentages (5, 10, 15, and 20 wt% CS/La2O3) were prepared via a simple solution casting method. The prepared CS/La2O3 nanocomposite solutions were cast in a Petri dish in order to produce the developed catalyst, which was shaped as a thin film. The structural features of the hybrid nanocomposite film were studied by FTIR, SEM, and XRD analytical tools. FTIR spectra confirmed the presence of the major characteristic peaks of chitosan, which were modified by interaction with La2O3 nanoparticles. Additionally, SEM graphs showed dramatic morphological changes on the surface of chitosan, which is attributed to surface adsorption with La2O3 molecules. The prepared CS/La2O3 nanocomposite film (15% by weight) was investigated as an effective, recyclable, and heterogeneous base catalyst in the synthesis of pyridines and pyrazoles. The nanocomposite used was sufficiently stable and was collected and reused more than three times without loss of catalytic activity.

show abstract

“…SGLT2 inhibitors reduce blood glucose via inhibiting the reabsorption of glucose by the proximal renal tubules, resulting in osmotic diuresis and glycosuria, and its mechanism of action is insulin-independent. [ 6 , 7 ] However, one of the adverse reactions of SGLT2 inhibitors is an increase in LDL-C and HDL-C levels, which may increase the risk of cardiovascular disease. EMPA-REG OUTCOME ClinicalTrial [ 8 , 9 ] has shown that empagliflozin, used to treat type 2 diabetes mellitus, was associated with a mild increase in LDL-C and HDL-C in patients.…”

Section: Introductionmentioning

confidence: 99%

Effects of different dosages of Sodium-Glucose Transporter 2 Inhibitors on lipid levels in patients with type 2 diabetes mellitus

Cai

Gao²,

Zhang³

et al. 2020

Medicine

View full text Add to dashboard Cite

Background: Type 2 diabetes mellitus is one of the most common chronic diseases, which endangers peoples health and life qualities. Sodium-Glucose Transporter 2 (SGLT2) inhibitors have been widely recognized since their clinical application in blood glucose control. While, dyslipidemia caused by SGLT2 inhibitors has been identified that affected the prognosis of this disease. Methods: We will retrieve 8 databases including English and Chinese. After multiple screening, all randomized controlled trials (RCTs) related to SGLT2 inhibitors will be included by the 2 authors and data will be extracted. After completion of the risk of bias assessment, we will use these effect values including risk ratio (RR), weighted mean difference (WMD) and 95% confidence interval (CI) to conduct data analysis. Chi-Squared test and I 2 test will be used to assess heterogeneity between studies. The robustness of meta-analysis results will be determined by sensitivity analysis. It will be assessed that evidence quality of the outcomes on the GRADE. Results: The results of our research will be published in a peer-reviewed journal. Conclusion: The purpose of this systematic review and meta-analysis is to evaluate the association and degree of association between different doses of SGLT2 inhibitors and changes on blood lipid levels in patients with type 2 diabetes mellitus, in order to provide a reliable basis for clinical medication. INPLASY registration number: INPLASY202040201.

show abstract

Recent Progress of Sodium-Glucose Transporter 2 Inhibitors as Potential Antidiabetic Agents

Cited by 8 publications

References 84 publications

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease

Synthesis of Chitosan-La2O3 Nanocomposite and Its Utility as a Powerful Catalyst in the Synthesis of Pyridines and Pyrazoles

Effects of different dosages of Sodium-Glucose Transporter 2 Inhibitors on lipid levels in patients with type 2 diabetes mellitus

Contact Info

Product

Resources

About